The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma
Abstract
PURPOSE: To evaluate the pharmacokinetics and toxicity of an antisense oligonucleotide targeting bcl-2 in patients with non-Hodgkin’s lymphoma (NHL) and to determine efficacy using clinical and biologic end points. PATIENTS AND METHODS: Twenty-one patients with Bcl-2–positive relapsed NHL received a 14-day subcutaneous infusion of G3139, an 18-mer phosphorothioate oligonucleotide complementary to the first six codons of the bcl-2 open reading frame. Plasma pharmacokinetics were measured by anion exchange high-performance liquid chromatography. Response was assessed by computed tomography. Changes in Bcl-2 expression were measured by fluorescence-activated cell sorting of patients’ tumor samples. RESULTS: Eight cohorts of patients received doses between 4.6 and 195.8 mg/m 2/d. No significant systemic toxicity was seen at doses up to 110.4 mg/m 2/d. All patients displayed skin inflammation at the subcutaneous infusion site. Dose-limiting toxicities were thrombocytopenia, hypotension, fever, and asthenia. The maximum-tolerated dose was 147.2 mg/m 2/d. Plasma levels of G3139 equivalent to the efficacious plasma concentration in in vivo models were produced with doses above 36.8 mg/m 2/d. Plasma levels associated with dose-limiting toxicity were greater than 4 μg/mL. By standard criteria, there was one complete response, 2 minor responses, nine cases of stable disease, and nine cases of progressive disease. Bcl-2 protein was reduced in seven of 16 assessable patients. This reduction occurred in tumor cells derived from lymph nodes in two patients and from peripheral blood or bone marrow mononuclear cell populations in the remaining five patients. CONCLUSION: Bcl-2 antisense therapy is feasible and shows potential for antitumor activity in NHL. Downregulation of Bcl-2 protein suggests a specific antisense mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Veis, D. J., Sorenson, C. M., Shutter, J. R., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80065-m · Cited by 1,628
BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.
Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M., & Korsmeyer, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.6961 · Cited by 1,252
Massive Cell Death of Immature Hematopoietic Cells and Neurons in Bcl-x-Deficient Mice
Motoyama, N., Wang, F., Roth, K. A., Sawa, H., Nakayama, K.-I., Nakayama, K., Negishi, I., Senju, S., Zhang, Q., Fujii, S., et al. (1995) · Science · doi:10.1126/science.7878471 · Cited by 1,163
McDonnell, T. J., & Korsmeyer, S. J. (1991) · Nature · doi:10.1038/349254a0 · Cited by 858
Ballas, Z. K., Rasmussen, W. L., & Krieg, A. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.1840 · Cited by 754
Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C., & Vogel, J. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3042 · Cited by 541
Gascoyne, R. D., Adomat, S. A., Krajewski, S., Krajewska, M., Horsman, D. E., Tolcher, A. W., O'Reilly, S. E., Hoskins, P., Coldman, A. J., Reed, J. C., et al. (1997) · Blood · doi:10.1182/blood.v90.1.244 · Cited by 509
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
Webb, A., Cunningham, D., Cotter, F., Clarke, P., Di Stefano, F., Ross, P., Corbo, M., & Dziewanowska, Z. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11103-x · Cited by 489
Self-citationbcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., Van Elsas, A., Müller, M., Wolff, K., Eichler, H.-G., & Pehamberger, H. (1998) · Nature Medicine · doi:10.1038/nm0298-232 · Cited by 481
Miyashita, T., & Reed, J. C. (1992) · PubMed · Cited by 475
Hermine, O., Haioun, C., Lepage, E., d'Agay, M., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J., Diebold, J., et al. (1996) · Blood · doi:10.1182/blood.v87.1.265.265 · Cited by 452
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
Yacyshyn, B. R., Bowen-Yacyshyn, M. B., Jewell, L., Tami, J. A., Bennett, C. F., Kisner, D. L., & Shanahan, W. R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70418-4 · Cited by 381
Hill, M., MacLennan, K., Cunningham, D., Vaughan Hudson, B., Burke, M., Clarke, P., Di Stefano, F., Anderson, L., Vaughan Hudson, G., Mason, D., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1046.1046 · Cited by 314
Self-citationKamada, S., Shimono, A., Shinto, Y., Tsujimura, T., Takahashi, T., Noda, T., Kitamura, Y., Kondoh, H., & Tsujimoto, Y. (1995) · PubMed · Cited by 225
McDonnell, T. J., Nunez, G., Platt, F. M., Hockenberry, D., London, L., McKearn, J. P., & Korsmeyer, S. J. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.5.1901 · Cited by 221
Wooldridge, J. E., Ballas, Z., Krieg, A. M., & Weiner, G. J. (1997) · Blood · doi:10.1182/blood.v89.8.2994 · Cited by 203
KITADA, S., TAKAYAMA, S., DE RIEL, K., TANAKA, S., & REED, J. C. (1994) · Antisense Research and Development · doi:10.1089/ard.1994.4.71 · Cited by 185
Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.
Cotter, F. E., Johnson, P., Hall, P. A., Pocock, C., al Mahdi, N., Cowell, J. K., & Morgan, G. J. (1994) · PubMed · Cited by 180
Self-citationZangemeister-Wittke, U., Schenker, T., Luedke, G., & Stahel, R. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.624 · Cited by 162
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.
Bishop, M. R., Iversen, P. L., Bayever, E., Sharp, J. G., Greiner, T. C., Copple, B. L., Ruddon, R., Zon, G., Spinolo, J., Arneson, M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1320 · Cited by 136
Glover, J. M., Leeds, J. M., Mant, T., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., & Shanahan, W. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36939-3 · Cited by 135
Zhang, R., Yan, J., Shahinian, H., Amin, G., Lu, Z., Liu, T., Saag, M. S., Jiang, Z., Temsamani, J., Martin, R. R., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90071-3 · Cited by 129
Stevenson, J. P., Yao, K.-S., Gallagher, M., Friedland, D. P., Mitchell, E. P., Cassella, A., Monia, B. P., Kwoh, T. J., Yu, R. Z., Holmlund, J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2227 · Cited by 129
Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R., & Nicklin, P. L. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00190-1 · Cited by 103
Primitive human hematopoietic precursors express Bcl-x but not Bcl-2
Park, J., Bernstein, I. D., & Hockenbery, D. M. (1995) · Blood · doi:10.1182/blood.v86.3.868.868 · Cited by 99
Investigations of Antisense Oligonucleotides Targeted Against bcl-2 RNAs
Kitada, S., Miyashita, T., Tanaka, S., & REED, J. C. (1993) · Antisense Research and Development · doi:10.1089/ard.1993.3.157 · Cited by 94
Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D., & Levin, A. A. (1997) · PubMed · Cited by 90
Effects of synthetic oligonucleotides on human complement and coagulation∗
Shaw, D. R., Rustagi, P. K., Kandimalla, E. R., Manning, A. N., Jiang, Z., & Agrawal, S. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00091-9 · Cited by 48
Cited by
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
The Bcl-2 family: roles in cell survival and oncogenesis
Cory, S., Huang, D. C. S., & Adams, J. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207102 · Cited by 1,463
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc749 · Cited by 1,349
Targeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Metadata
- Authors
- Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., & Cotter, F. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-05-09
- Volume
- 18
- Issue
- 9
- Pages
- 1812-1823
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2290539832
- Cited by
- 454
- References
- 29
- FWCI
- 39.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.